Re: Saint-Laurent Thibault C, Moorjaney D, Ganz ML, et al. Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States. J Med Econ 2017;20:692-702

  • Jayeshkumar Patel, Xiaohui Zhao, Drishti Shah, Khalid Alhussain, Khalid Kamal
  • Journal of Medical Economics, August 2017, Taylor & Francis
  • DOI: 10.1080/13696998.2017.1360310

The authors haven't yet claimed this publication.

Read Publication

http://dx.doi.org/10.1080/13696998.2017.1360310